TTY Biopharm Company Limited (TPEX:4105)

TTY Biopharm Company Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	2,773	2,621	2,357	2,222	2,224
Short-Term Investments	309.02	195.54	326.86	372.65	342.4
Cash & Short-Term Investments	3,082	2,817	2,684	2,595	2,566
Cash Growth	9.41%	4.93%	3.44%	1.12%	-11.66%
Accounts Receivable	1,354	1,344	1,227	1,138	1,033
Other Receivables	23.18	28.81	29.68	13.62	16.48
Receivables	1,377	1,373	1,257	1,151	1,050
Inventory	1,270	1,096	1,039	955.01	1,111
Prepaid Expenses	57.91	79.02	49.89	46.96	64.15
Other Current Assets	6.67	6.36	5.37	1.15	8.01
Total Current Assets	5,793	5,370	5,035	4,749	4,799
Property, Plant & Equipment	2,246	2,287	2,433	2,519	2,585
Long-Term Investments	1,945	1,578	1,496	1,432	1,458
Goodwill	247.9	-	-	-	-
Other Intangible Assets	123.44	164.01	250.75	124.9	132.9
Long-Term Deferred Tax Assets	58.52	48.71	47.1	63.72	61.8
Other Long-Term Assets	448.25	426.94	337.89	407.19	324.72
Total Assets	10,863	9,875	9,601	9,296	9,361
Accounts Payable	326.16	294.66	289.4	187.27	159.44
Short-Term Debt	1,200	1,450	1,370	1,711	1,715
Current Portion of Long-Term Debt	400	-	418.85	407.91	16.54
Current Portion of Leases	0.93	5.86	3.92	7.62	-
Current Income Taxes Payable	228.8	156.97	149.52	150.39	110.13
Current Unearned Revenue	34.34	14.23	33.13	39.77	16.29
Other Current Liabilities	672.18	662.02	652.62	547.55	531.2
Total Current Liabilities	2,862	2,584	2,917	3,052	2,549
Long-Term Debt	100	400	9.6	4.15	412.05
Long-Term Leases	10.2	3.05	3.04	14.16	-
Long-Term Deferred Tax Liabilities	359.24	318.75	305.44	260.52	271.83
Other Long-Term Liabilities	2.44	35.83	91.03	146.23	4.7
Total Liabilities	3,352	3,369	3,367	3,529	3,283
Common Stock	2,487	2,487	2,487	2,487	2,487
Additional Paid-In Capital	317.04	316.62	312.18	311.88	338
Retained Earnings	3,888	3,182	2,925	2,568	2,759
Comprehensive Income & Other	58.69	-43.79	-64.78	-198.07	-133.71
Total Common Equity	6,750	5,941	5,658	5,168	5,450
Minority Interest	760.49	564.8	574.86	599.38	628.3
Shareholders' Equity	7,511	6,506	6,233	5,767	6,078
Total Liabilities & Equity	10,863	9,875	9,601	9,296	9,361
Total Debt	1,711	1,859	1,805	2,145	2,144
Net Cash (Debt)	1,371	957.65	878.78	450	422.47
Net Cash Growth	43.11%	8.97%	95.28%	6.52%	-56.51%
Net Cash Per Share	5.50	3.84	3.53	1.81	1.70
Filing Date Shares Outstanding	248.65	248.65	248.65	248.65	248.65
Total Common Shares Outstanding	248.65	248.65	248.65	248.65	248.65
Working Capital	2,931	2,787	2,118	1,698	2,250
Book Value Per Share	27.15	23.89	22.76	20.78	21.92
Tangible Book Value	6,379	5,777	5,408	5,043	5,317
Tangible Book Value Per Share	25.65	23.23	21.75	20.28	21.38
Land	902.9	902.9	902.9	902.9	902.9
Buildings	1,479	1,461	1,432	1,420	1,311
Machinery	1,446	1,432	1,418	1,359	1,234
Construction In Progress	0.59	8.95	77.09	95	323.33

Updated Feb 26, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.